-Stabilizing Long Noncoding RNA Promotes Hormone-Refractory Breast Cancer Progression

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2019 Sep 11

PMID 31501276

Citations 35

Authors

Yuichi Mitobe

Kazuhiro Ikeda

Takashi Suzuki

Kiyoshi Takagi

Hidetaka Kawabata

Kuniko Horie-Inoue

Satoshi Inoue

Affiliations

Soon will be listed here.

Abstract

Acquired endocrine therapy resistance is a significant clinical problem for breast cancer patients. In recent years, increasing attention has been paid to long noncoding RNA (lncRNA) as a critical modulator for cancer progression. Based on RNA-sequencing data of breast invasive carcinomas in The Cancer Genome Atlas database, we identified thymopoietin antisense transcript 1 () as a functional lncRNA that significantly correlates with proliferative biomarkers. positivity analyzed by hybridization significantly correlates with poor prognosis of breast cancer patients. expression was upregulated in endocrine therapy-resistant MCF-7 cells compared with levels in parental cells and was estrogen inducible. Gain and loss of experiments showed that promotes the proliferation and viability of estrogen receptor (ER)-positive breast cancer cells and Global expression analysis using a microarray demonstrated that is closely associated with the estrogen signaling pathway. could positively regulate estrogen receptor 1 () mRNA expression by stabilizing mRNA through interaction with mRNA. Enhanced expression of mRNA by could play a critical role in the proliferation of ER-positive breast cancer. Our findings provide a new insight into the understanding of molecular mechanisms underlying hormone-dependent breast cancer progression and endocrine resistance.

Citing Articles

LURAP1L-AS1 long noncoding RNA promotes breast cancer progression and associates with poor prognosis.

Vishnubalaji R, Awata D, Alajez N Noncoding RNA Res. 2025; 12:1-9.

PMID: 39995981 PMC: 11847224. DOI: 10.1016/j.ncrna.2025.01.006.

Long Non-Coding RNAs, Nuclear Receptors and Their Cross-Talks in Cancer-Implications and Perspectives.

Tiwari P, Tripathi L Cancers (Basel). 2024; 16(16).

PMID: 39199690 PMC: 11352509. DOI: 10.3390/cancers16162920.

Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer.

Lee J, Kim E, Kang J, Chae Y, Park H, Kang B BMC Mol Cell Biol. 2024; 25(1):12.

PMID: 38649821 PMC: 11036730. DOI: 10.1186/s12860-024-00510-y.

Liquid biopsy using non-coding RNAs and extracellular vesicles for breast cancer management.

Hashimoto K, Ochiya T, Shimomura A Breast Cancer. 2024; 32(1):16-25.

PMID: 38512533 DOI: 10.1007/s12282-024-01562-w.

Neat1 lncRNA organizes the inflammatory gene expressions in the dorsal root ganglion in neuropathic pain caused by nerve injury.

Maruyama M, Sakai A, Fukunaga T, Miyagawa Y, Okada T, Hamada M Front Immunol. 2023; 14:1185322.

PMID: 37614230 PMC: 10442554. DOI: 10.3389/fimmu.2023.1185322.

References

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

Misawa A, Takayama K, Urano T, Inoue S . Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells. J Biol Chem. 2016; 291(34):17861-80. PMC: 5016176. DOI: 10.1074/jbc.M116.718536. View

Sun M, Gadad S, Kim D, Kraus W . Discovery, Annotation, and Functional Analysis of Long Noncoding RNAs Controlling Cell-Cycle Gene Expression and Proliferation in Breast Cancer Cells. Mol Cell. 2015; 59(4):698-711. PMC: 4546522. DOI: 10.1016/j.molcel.2015.06.023. View

Ghoncheh M, Pournamdar Z, Salehiniya H . Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac J Cancer Prev. 2016; 17(S3):43-6. DOI: 10.7314/apjcp.2016.17.s3.43. View

Bussemakers M, van Bokhoven A, Verhaegh G, Smit F, Karthaus H, Schalken J . DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59(23):5975-9. View

Faghihi M, Modarresi F, Khalil A, Wood D, Sahagan B, Morgan T . Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 2008; 14(7):723-30. PMC: 2826895. DOI: 10.1038/nm1784. View

Mitobe Y, Takayama K, Horie-Inoue K, Inoue S . Prostate cancer-associated lncRNAs. Cancer Lett. 2018; 418:159-166. DOI: 10.1016/j.canlet.2018.01.012. View

Leivonen S, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K . Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. 2009; 28(44):3926-36. DOI: 10.1038/onc.2009.241. View

Musgrove E, Sutherland R . Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9(9):631-43. DOI: 10.1038/nrc2713. View

10.

Zhang Y, Pitchiaya S, Cieslik M, Niknafs Y, Tien J, Hosono Y . Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nat Genet. 2018; 50(6):814-824. PMC: 5980762. DOI: 10.1038/s41588-018-0120-1. View

11.

Engreitz J, Sirokman K, McDonel P, Shishkin A, Surka C, Russell P . RNA-RNA interactions enable specific targeting of noncoding RNAs to nascent Pre-mRNAs and chromatin sites. Cell. 2014; 159(1):188-199. PMC: 4177037. DOI: 10.1016/j.cell.2014.08.018. View

12.

Ikeda K, Horie-Inoue K, Ueno T, Suzuki T, Sato W, Shigekawa T . miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. Sci Rep. 2015; 5:13170. PMC: 4530347. DOI: 10.1038/srep13170. View

13.

Oyama M, Nagashima T, Suzuki T, Kozuka-Hata H, Yumoto N, Shiraishi Y . Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer. J Biol Chem. 2010; 286(1):818-29. PMC: 3013041. DOI: 10.1074/jbc.M110.156877. View

14.

Sharma E, Sterne-Weiler T, OHanlon D, Blencowe B . Global Mapping of Human RNA-RNA Interactions. Mol Cell. 2016; 62(4):618-26. DOI: 10.1016/j.molcel.2016.04.030. View

15.

Bhan A, Mandal S . Estradiol-Induced Transcriptional Regulation of Long Non-Coding RNA, HOTAIR. Methods Mol Biol. 2015; 1366:395-412. DOI: 10.1007/978-1-4939-3127-9_31. View

16.

Huang W, Su X, Yan W, Kong Z, Wang D, Huang Y . Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer. Prostate. 2018; 78(16):1248-1261. DOI: 10.1002/pros.23700. View

17.

Torres M, Becquet D, Guillen S, Boyer B, Moreno M, Blanchard M . RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA. J Vis Exp. 2018; (134). PMC: 5933463. DOI: 10.3791/57379. View

18.

Ujihira T, Ikeda K, Suzuki T, Yamaga R, Sato W, Horie-Inoue K . MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer. Sci Rep. 2015; 5:7641. PMC: 4284514. DOI: 10.1038/srep07641. View

19.

Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H . Precision medicine for metastatic breast cancer--limitations and solutions. Nat Rev Clin Oncol. 2015; 12(12):693-704. DOI: 10.1038/nrclinonc.2015.123. View

20.

Guil S, Esteller M . RNA-RNA interactions in gene regulation: the coding and noncoding players. Trends Biochem Sci. 2015; 40(5):248-56. DOI: 10.1016/j.tibs.2015.03.001. View